Ascent Equity Partners and IBK Capital have jointly invested 30 billion KRW in HanDoc Co., underscoring bankable cash flows and a strategic growth outlook within the pharmaceutical sector in South Korea.

Information on the Target

HanDoc Co., a publicly listed pharmaceutical company in South Korea, has attracted significant investment from Ascent Equity Partners (Ascent EP) and IBK Capital, amounting to 30 billion KRW. This investment comes as HanDoc has demonstrated strong cash-generating capabilities, underscored by its diverse product portfolio that includes ethical drugs, over-the-counter medicines, medical devices, diagnostic agents, and health supplements.

Over the past seven years, HanDoc has maintained impressive financial performance, recording an average EBITDA of 44.2 billion KRW. The company has established itself with several flagship products, notably in the diabetes treatment sector, including Amaryl, which is recognized for its efficacy and stability, and Tenelia, a blood glucose regulator for adults with type 2 diabetes.

Industry Overview in South Korea

The pharmaceutical sector in South Korea is experiencing robust growth, propelled by increasing healthcare expenditures and a rising chronic patient population driven by Western dietary hab